Zimmer Biomet Holdings has been mandated to continue paying royalties on knee replacement devices it developed using patents from an orthopedic surgeon, even though those patents have expired. The Seventh Circuit upheld a lower court’s decision on Friday, affirming an arbitration ruling in favor of the surgeon’s estate. According to the ruling, the expiration of the patents does not absolve Zimmer Biomet from its contractual obligations to the estate.
For further details, you can refer to the full report on Law360.